Femasys Inc (FEMY)

Überblick Nachrichten Preisverlauf Financials Warum fällt FEMY? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Femasys Inc Stock (FEMY) Company Profile

Healthcare (1087)

770-500-3910

3950 JOHNS CREEK COURT, SUWANEE

Nächster Verdiensttermin

Neueste SEC-Einreichungen

FEMY's Discussions on Twitter

Compare FEMY vs ISRG, BDX, ALC, RMD, MDLN

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FEMY Femasys Inc	2.75	22.45M	2.38M	-12.40M	-18.68M	-6.4626
ISRG Intuitive Surgical Inc	351.37	123.70B	11.03B	3.16B	3.22B	8.7251
BDX Becton Dickinson Co	180.39	48.78B	21.37B	1.41B	3.07B	3.9437
ALC Alcon Inc	69.06	33.41B	10.63B	819.00M	1.59B	1.6577
RMD Resmed Inc	219.84	31.89B	5.54B	1.52B	1.74B	10.37
MDLN Medline Inc	34.35	30.44B	29.14B	1.07B	1.05B	1.1956

Femasys Inc Stock (FEMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-20	Eingeleitet	Laidlaw	Buy

Femasys Inc Aktie (FEMY) Neueste Nachrichten

Finanzdaten der Femasys Inc-Aktie (FEMY)

Femasys Inc-Aktie (FEMY) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Sipos Jeremy Alexander	Chief Technology Officer	Aug 07 '26	Buy	3.20	3,125	10,000	3,125
Canning John Charles	Chief Operating Officer	Aug 07 '26	Buy	3.20	4,375	14,000	4,375
Elefant Dov	Chief Financial Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625
Lee-Sepsick Kathy	Chief Executive Officer	Aug 07 '26	Buy	3.20	15,625	50,000	15,625

Femasys Inc (FEMY)

Femasys Inc Stock (FEMY) Company Profile

Compare FEMY vs ISRG, BDX, ALC, RMD, MDLN

Femasys Inc Stock (FEMY) Upgrades & Downgrades

Femasys Inc Aktie (FEMY) Neueste Nachrichten

Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us

Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus

FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView

Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan

FEMASYS INC (FEMY) Stock Price & Overview - ChartMill

Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Femasys Inc (FEMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan

Femasys (FEMY) Stock News & Analysis - TechStock²

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times

Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn

Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn

Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn

Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan

Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm

Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com

Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView

Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria

Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance

FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan

Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com

Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record

Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView

Femasys secures $30 million to advance fertility portfolio - The Pharma Letter

Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan

FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn

Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo

Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade

Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan

Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView

Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative

Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan

Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake - Stock Titan

FEMY Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Slips 2.55%Earnings Decline Risk - vinanet.vn

FEMY Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share, Yet Shares Dip 2.34%ROIC Trend Report - Vinanet

Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents - marketscreener.com

Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share Beats Estimates by 34.64% - dars.gov.et

Femasys receives patents for FemBloc birth control polymer By Investing.com - Investing.com South Africa

Femasys receives patents for FemBloc birth control polymer - Investing.com

Femasys Secures New U.S. and International Patents for FemBloc Blended Polymer, Expanding Global IP Protection - Quiver Quantitative

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents - Yahoo Finance

Femasys COO John Canning buys $14,000 in FEMY stock - Investing.com India

Femasys COO John Canning buys $14,000 in FEMY stock By Investing.com - Investing.com South Africa

Femasys chief clinical-medical affairs Mifek buys $10,000 stock By Investing.com - Investing.com Australia

Finanzdaten der Femasys Inc-Aktie (FEMY)

Umsatz

Nettogewinn

Free Cashflow

ENV

Femasys Inc-Aktie (FEMY) Insiderhandel

Ähnlich wie FEMY